Frank R. Ruderman

Frank Ruderman is the Chief Executive Officer, Chairman of the Board, and a Managing Partner of Tenex Greenhouse Ventures.

Additionally, Mr. Ruderman is the Chairman and CEO of Berkeley HeartLab. He is also a founder of Tenex Medical Investors, an organization of angel investors with an exclusive focus in the life sciences. He serves on the Board of Directors of Watergate Software, and is also a member of the Global Advisory Board of the Asian Business Association.

Mr. Ruderman had been a consultant and a director of Genomyx from its founding at Genentech with Human Genome Project funding, later acting as President/CEO and CFO. Genomyx was sold to Beckman Instruments. He founded and acted President, COO and a Director of Physiometrix, which went public at a $60 million valuation. Mr. Ruderman also helped to found two additional medical device companies, Intella Interventional (private) and Cardiac Pathways (public at a $200 million valuation) as spin-outs of Physiometrix. Mr. Ruderman served as a Board member, President, COO and CFO of American Bionetics, which saw revenue growth of 5x and its stock price increased to a high of 8x, the IPO price. The Company was sold to BioGenex after finalizing two acquisitions and completing joint ventures with Millipore and Dupont. He served as a member of the Board and the first President/CEO of Mast Immunosystems, which was sold to Hitachi. Before that, Mr. Ruderman served in various domestic and international corporate executive positions with Pfizer Pharmaceuticals, Pfizer Diagnostics and Millipore.
 

Mr. Ruderman has an M.B.A. from the Amos Tuck School of Business at Dartmouth College, an M.A. in vascular physiology from Boston University, and a B.S. in biology from Tufts University.
 

Robert E. Leach

Robert Leach is the President, Chief Operating Officer, and a Managing Partner of Tenex Greenhouse Ventures. He is responsible for smooth running the Greenhouse fund, ensuring that deals are well represented and that there is sufficient deal flow.

Mr. Leach served as Chairman and CEO of EPIcyte Pharmaceutical. He completed an angel financing followed by the Company's first venture capital round. He also completed a strategic alliance with Dow Chemical providing some $50 Million of value to the Company. Mr. Leach founded CEO Consulting to assist biotechnology companies through transition, and typically would serve as an interim CEO. He initiated and completed the merger of two client companies. Mr. Leach was appointed Chief Operating Officer of CONNECT, the University of California San Diego's innovative program in Technology and Entrepreneurship. In this capacity he and the CONNECT staff worked with over 300 early stage high technology companies. Mr. Leach was formerly the President and Chief Executive Officer of Genencor International. Genencor is now number 2 in its industry with revenues of over $300 million and 1300 employees, and has been sold to Eastman Kodak and Cultor Limited of Europe. Prior to Genecor, he worked at Corning Inc.

Mr. Leach has an M.B.A. from the Smeal College of Business at Pennsylvania State University and a B.S. from Pennsylvania State University.

Dr. Timothy Mills

Dr. Timothy Mills is a Managing Partner of Tenex Greenhouse Ventures. His focus is on selecting portfolio companies for which Sanderling might be interested in providing follow-on funding.

With over fifteen years of experience in biomedical research and corporate management, Dr. Timothy Mills joined Sanderling as an Operating Partner and was subsequently promoted to General Partner. At Sanderling, Dr. Mills has focused on early stage investments in medical devices, biotherapeutics, and i-Health. He serves Sanderling portfolio companies as Director, Chief Executive Officer or management team member.

Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics, a medical device company that was acquired by Boston Scientific for $1.2 billion. He also served as the Director for Prograft Medical, a Target affiliate. Prior to joining Target, Dr. Mills served as Director of Business Development and Advanced Research & Development in the Interventional Cardiology Division of Baxter Healthcare. Dr. Mills' academic appointments include service as the Director of the Artificial Heart Program at the University of California, Irvine Medical Center and membership in the University of California, San Francisco Radiology Department.

Dr. Mills received his Ph.D. in Bioengineering from the University of California, Berkeley & San Francisco School of Medicine, his M.S. in Electrical Engineering & Computer Science from the University of California, Berkeley, and his B.S. in Electrical Engineering from the University of Colorado, Boulder.
 

Paul D. Quadros

Paul D. Quadros is a Managing Partner of Tenex Greenhouse Ventures. He is involved in the screening and selection process of portfolio companies for the greenhouse.

Additionally, Mr. Quadros is currently Chairman of the Board of GenStar Therapeutics Corp., a developer of gene therapies to treat Hemophilia A and prostate cancer. Mr. Quadros is a founder of Tenex Medical Investors, an organization of angel investors with an exclusive focus in the life sciences. He served as Chairman of the Investment Screening Committee. Mr. Quadros is a founder and Chairman of Cardiac Science, a developer of automatic external defibrillator devices and software and TheraCyte, Inc., a manufacturer and distributor of devices that allow human cell transplants without immunosuppression. He is also a founder and serves on the Board of Directors of cancerfacts.com, an Internet enabled disease management tools company, and AuthCath Vascular Access, a developer of proprietary venous access systems. Mr. Quadros is also an advisor to ENDOcare, Inc., a developer and manufacturer of surgical systems and devices and Spectrascan Health Services, the largest provider of mammography services in the United States. Mr. Quadros also served as a consultant and as a member of the Board of Directors of NeoVision Corporation, a developer of diagnostic and image guided therapy equipment. NeoVision was sold to U.S. Surgical Corporation.

Mr. Quadros founded GenStar and served as its President and CEO when a strategic partnership alliance with Baxter Healthcare Corporation was completed. He was a General Partner of Technology Funding, a venture capital management organization. He joined Technology Funding as a Senior Vice President and was elected a General Partner. Mr. Quadros was a member of Technology Funding's Commitments Committee, also serving as its Chairman. During his affiliation with Technology Funding, he also served as Director of Investment Research and Director of Equity Investments. Mr. Quadros served as Chairman of Technology Funding's Medical Investment Committee and was actively involved in managing Technology Funding's healthcare portfolio.

Mr. Quadros holds a B.A. in Finance from California State University at Fullerton and an MBA from the UCLA Graduate School of Management.